The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Functional BRM promoter polymorphisms, pancreatic adenocarcinoma risk, and survival.
Maja Segedi
No relevant relationships to disclose
Laura N Anderson
No relevant relationships to disclose
Osvaldo Espin-Garcia
No relevant relationships to disclose
Ayelet Borgida
No relevant relationships to disclose
Teresa Bianco
No relevant relationships to disclose
Dangxiao Cheng
No relevant relationships to disclose
Zhuo Chen
No relevant relationships to disclose
Devalben Patel
No relevant relationships to disclose
M Catherine Brown
No relevant relationships to disclose
Rayjean J Hung
No relevant relationships to disclose
Michelle Cotterchio
No relevant relationships to disclose
Steven Gallinger
No relevant relationships to disclose
Wei Xu
No relevant relationships to disclose
David Reisman
Stock Ownership - Zenagene
Geoffrey Liu
No relevant relationships to disclose
Sean P. Cleary
No relevant relationships to disclose